We are developing a pipeline for various VLP based vaccines for both livestock and human use and have already succeeded in the commercialization of several vaccines.
The VLP vaccine technology we are developing is the new generation solution to the safety issues and low efficacy of existing recombinant vaccines. It has resolved low productivity rates and has simplified the complicated refinement process in existing VLP development, presenting a vast improvement in the commercial complex vaccine technology market.